Plasma Proteomics Biomarkers in Psoriasis Patients Undergoing Secukinumab Therapy

Hongyang Zhang published longitudinal plasma proteomic data from a study of 10 psoriasis patients and 10 healthy controls. The dataset quantifies 92 inflammation-related proteins using the Olink platform to identify diagnostic and response biomarkers for secukinumab therapy. The data was uploaded to figshare on April 24, 2026.

Use Cases

• Identify diagnostic biomarkers for psoriasis based on baseline plasma protein profiles.
• Analyze longitudinal changes in inflammatory mediators following IL-17A inhibition.
• Correlate baseline protein levels, such as IL-17C, with disease severity and therapeutic response.
• Perform functional enrichment analysis on differentially expressed proteins involved in cytokine signaling pathways.
• Validate candidate circulating biomarkers for disease monitoring in psoriasis.

Strengths

• Includes longitudinal data from patients before and during therapy.
• Quantifies 92 specific inflammation-related proteins using the Olink Target 96 panel.
• Contains matched data from 10 healthy controls for comparison.
• Key findings, such as CXCL1, CXCL5, CCL20, and HGF alterations, are validated by ELISA.

Limitations

• The sample size is small, with only 10 patients and 10 controls.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Plasma samples analyzed using the Olink Target 96 Inflammation panel; longitudinal patterns assessed with Mfuzz clustering.

Freshness

Last updated 2026-04-24 05:40:22; freshness should be verified.